Cargando…
Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry
INTRODUCTION: The benefits and use of low-dose corticosteroids (LDCs) in severe sepsis and septic shock remain controversial. Surviving sepsis campaign guidelines suggest LDC use for septic shock patients poorly responsive to fluid resuscitation and vasopressor therapy. Their use is suspected to be...
Autores principales: | Beale, Richard, Janes, Jonathan M, Brunkhorst, Frank M, Dobb, Geoffrey, Levy, Mitchell M, Martin, Greg S, Ramsay, Graham, Silva, Eliezer, Sprung, Charles L, Vallet, Benoit, Vincent, Jean-Louis, Costigan, Timothy M, Leishman, Amy G, Williams, Mark D, Reinhart, Konrad |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911744/ https://www.ncbi.nlm.nih.gov/pubmed/20525247 http://dx.doi.org/10.1186/cc9044 |
Ejemplares similares
-
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
por: Martin, Greg, et al.
Publicado: (2009) -
The International Sepsis Forum's controversies in sepsis: corticosteroids should be used to treat septic shock
por: Goodman, Sergey, et al.
Publicado: (2002) -
Antimicrobial treatment in patients with severe sepsis and septic shock: results from the German Prevalence Study
por: Brunkhorst, F, et al.
Publicado: (2006) -
Rate of microbiologically proven infections among patients with severe sepsis/septic shock: results from the German prevalence study
por: Brunkhorst, F, et al.
Publicado: (2006) -
Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)